Taiho Pharmaceutical Company Limited

Pioneer Corporation

Taiho Pharmaceutical

Yuji Yamada

Tetsuji Asao

Ichiro Yamawaki

Teruhiro Utsugi

Shinji Okazaki

Keisuke Ishida

Motoji Wakida

Mitsugi Yasumoto

Konstanty Wierzba

Masato Washinosu

Yoshikazu Sugimoto

Kenji Suzuki

Setsuo Takeda

Akihide Koda

Katsuo Takikawa

Mikio Hori

Kazutaka Miyadera

Hitoshi Saito

Yoshinori Minami

Toshio Ohtani

Teruyoshi Marunaka

Tian Jie

Qi Chang-qing

Ken-ichi Matsuo

Koichi Shudo

Kazuo Ogawa

Norio Unemi

Junichi Yamashita

Tomohiro Emura

Tadafumi Terada

Katsuhiko Fujimoto

Norio Masuko

Junji Uchida

Tomonori Nakada

Koji Murakami

Yuji Takebayashi

Kazuharu Noguchi

Toshiyuki Toko

Shinichi Akiyama

Jiro Shibata

A recording/reproducing mechanismincludes a pickup mechanism irradiating light on a disc recording medium, a pickup feed mechanism moving the pickup mechanism, and a flat coverhaving an openingA cut along a feeding direction of the pickup mechanism. The flat coveris supported elastically in a direction toward and away from the tray. The trayhas a recessed portion allowing the flat coverto move in the direction toward and away from the tray. A protrusionis provided on the recessed portion to restrict deformation of the flat coverand prevents the flat coverfrom contacting to the disc recording medium upon dropping impact. Therefore, even if the edge of the openingA of the flat coveris turned up due to the impact when the driver housing the disc recording mediumtherein is dropped, the edge contacts to the protrusion

Recording medium driving device

The present invention relates to a naphthalimidobenzamide derivative represented by the following formula (1):

Naphthalimidobenzamide derivatives

This invention provides a drug which has inhibitory activities against thymidine phosphorylase and inhibits metastasis of a cancer. Specifically, this invention relates to a cancerous metastasis inhibitor comprising, as an active ingredient, a uracil derivative represented by the following formula (1):

Cancerous metastasis inhibitors containing uracil derivatives

Double-stranded oligonucleotide and anticancer agent containing the same

A condensed-indan derivative represented by formula (1) and a pharmaceutically acceptable salt thereof: wherein ring A represents an optionally substituted benzene ring or naphthalene ring, or a benzene ring having a lower alkylenedioxy group, ring B represents an optionally substituted benzene ring or a benzene ring having a lower alkylenedioxy group. Y represents --N.dbd.CR-- or --CR.dbd.N--, R represents a --NR.sub.1 R.sub.2 group, an optionally substituted nitrogen-containing heterocyclic group or a --OR.sub.3 group, wherein R.sub.1 and R.sub.2 are the same or different and each is a hydrogen atom; a phenyl group; an optionally substituted nitrogen-containing heterocyclic group; or a lower alkyl group which may be substituted by at least one selected from the group consisting of an optionally substituted amino group, a lower alkoxy group, a phenyl group, a nitrogen-containing heterocyclic group, an amine oxide group substituted by a lower alkyl group or a hydroxyl group(s); R.sub.3 represents a lower alkyl group optionally substituted by a substituted amino group, except when R represents an optionally substituted nitrogen-containing heterocyclic group; ring A and ring B are a benzene ring having no substituent group.

Condensed-indan derivatives and pharmaceutically acceptable salts thereof

Triplex Oligonucleotides targeted to p120

Monoclonal antibodies

Condensed indan derivatives and salts thereof

Cancer metastasis inhibitor

Condensed-Indan derivatives and pharmaceutically acceptable salts thereof

A condensed-indan derivative represented by formula (1) and a pharmaceutically acceptable salt thereof: ##STR1## wherein ring A represents an optionally substituted naphthalene ring, ring B represents an optionally substituted benzene ring or a benzene ring having a lower alkylenedioxy group. Y represents --N.dbd.CR-- or --CR.dbd.N--, R represents a --NR.sub.1 R.sub.2 group, an optionally substituted nitrogen-containing heterocyclic group or a --OR.sub.3 group, wherein R.sub.1 and R.sub.2 are the same or different and each is a hydrogen atom; a phenyl group; an optionally substituted nitrogen-containing heterocyclic group; or a lower alkyl group which may be substituted by at least one selected from the group consisting of an optionally substituted amino group, a lower alkoxy group, a phenyl group, a nitrogen-containing heterocyclic group, an amine oxide group substituted by a lower alkyl group or a hydroxyl group(s); R.sub.3 represents a lower alkyl group optionally substituted by a substituted amino group.

This invention provides a 5-substituted uridine derivative of the formula ##STR1## wherein X is F or CF.sub.3, R.sub.1 and R.sub.2 each represent a group --OSi--(R.sub.4)(R.sub.5)(R.sub.6) (wherein R.sub.4, R.sub.5 and R.sub.6 represent C.sub.1 -C.sub.10 alkyl or the like), OH, aminoacyloxy group wherein the amino group may be substituted with lower alkyl group or carboxylalkylcarbonyloxy group, R.sub.3 is a group --OSi(R.sub.4)(R.sub.5)(R.sub.6), H, OH, aminoacyloxy group wherein the amino group may be substituted with lower alkyl group, or carboxylalkylcarbonyloxy group, and at least one of R.sub.1, R.sub.2 and R.sub.3 is a group --OSi--(R.sub.4)(R.sub.5)(R.sub.6), with the proviso that when X is fluorine atom, R.sub.3 is not hydrogen, and an intermediate for the preparation thereof, preparation processes of the derivative and anti-tumor agent containing the derivative as an active ingredient.

5-substituted uridine derivatives

1,1,2-triaryl-1-alkene derivatives

Disclosed are a compound of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and each represents a hydrogen atom, an alkyl group or an acyl group, process for the production thereof and use thereof. The compounds have an antitumor activity, and those wherein both of R.sub.1 and R.sub.2 represent a hydrogen atom or an acyl group are novel compounds.

Substance 4181-2 and its derivatives having anti-leukemia activity

Substance 4181-2

Growing community of inventors

Tokorozawa, Japan

Yuji Yamada